<DOC>
	<DOC>NCT01151423</DOC>
	<brief_summary>The purpose of this study is to determine whether anti-von Willebrand factor Nanobody is safe and effective as adjunctive treatment in patients with acquired thrombotic thrombocytopenic purpura (TTP). Patients will receive either placebo or anti-von Willebrand factor Nanobody as adjunctive therapy to plasma exchange.</brief_summary>
	<brief_title>Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)</brief_title>
	<detailed_description />
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
	<criteria>18 years of age or older Men or women willing to accept an acceptable contraceptive regimen Patients with clinical diagnosis of TTP Necessitating plasma exchange (one, single PE session prior to randomisation into the study is allowed) Patient accessible to followup Obtained, signed and dated informed consent Platelet count greater or equal to 100,000/ÂµL Severe active infection indicated by sepsis (requirement for pressors with or without positive blood cultures) Clinical evidence of enteric infection with E.coli 0157 or related organism Antiphospholipid syndrome Diagnosis of disseminated intravascular coagulation (DIC) Pregnancy or breastfeeding Haematopoietic stem cell or bone marrow transplantationassociated thrombotic microangiopathy Known congenital TTP Active bleeding or high risk of bleeding Uncontrolled arterial hypertension Known chronic treatment with anticoagulant treatment that can not be stopped safely Severe or life threatening clinical condition other than TTP that would impair participation in the trial Subjects with malignancies resulting in a life expectation of less than 3 months Subjects with known or suspected bone marrow carcinosis Subjects who cannot comply with study protocol requirements and procedures Known hypersensitivity to the active substance or to excipients of the study drug Severe liver impairment, corresponding to grade 3 toxicity defined by the CTCAE (common terminology criteria for adverse events) scale Severe chronic renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>